A novel anti‑EGFR monoclonal antibody (EMab‑17) exerts antitumor activity against oral squamous cell carcinomas via antibody‑dependent cellular cytotoxicity and complement‑dependent cytotoxicity
2017 ◽
Vol 36
(1)
◽
pp. 20-24
◽
2012 ◽
Vol 50
(3)
◽
pp. 134-141
◽
2017 ◽
Vol 36
(5)
◽
pp. 220-223
◽
2018 ◽
2007 ◽
Vol 27
(6)
◽
pp. 243-248
◽